Reported Safety Signals with Cosentyx Post-COVID Vaccination
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, has raised concerns for increased infection risk after COVID-19 vaccination. Real-world data from Israel's Clalit Health Services (over 27,000 psoriasis patients) showed vaccinated Cosentyx users had a 1.69-fold higher COVID-19 hospitalization risk versus unvaccinated peers on the drug, linked to older age and comorbidities rather than vaccination alone.[1] No causal link to vaccination was confirmed, but immunosuppressed patients on biologics like Cosentyx face breakthrough infections more often.
Does Cosentyx Affect Vaccine Response?
Cosentyx blunts immune responses to vaccines. A phase 4 trial (SECURE-SARS-CoV-2) found patients on secukinumab produced fewer neutralizing antibodies after mRNA COVID vaccines compared to healthy controls, though T-cell responses remained intact.[2] This humoral impairment persists for months post-vaccination, potentially reducing protection against variants. Guidelines from the National Psoriasis Foundation recommend continuing Cosentyx without pausing for vaccination, as benefits outweigh risks in most cases.[3]
Timing and Dosing Adjustments
No official delays are required, but experts advise vaccinating before starting Cosentyx if possible. The American College of Rheumatology suggests spacing biologics 1-2 weeks from vaccination for non-live shots, though evidence for Cosentyx specifically is limited.[4] Post-vaccination flares in psoriasis have been noted anecdotally, possibly from immune activation, but rates are low (under 5% in registries).[1]
Patient Risks and Monitoring
Higher concern applies to those over 65, with obesity, diabetes, or lung disease—groups already prone to severe COVID on Cosentyx. Post-vaccination monitoring includes watching for infections; one case series reported shingles reactivation shortly after both vaccine doses in secukinumab users.[5] Booster efficacy data is sparse, but ongoing studies (e.g., NCT05035895) track antibody waning.
What Doctors and Guidelines Say
Rheumatology societies (EULAR, ACR) classify Cosentyx as low-risk for pausing around vaccination, unlike JAK inhibitors. Continue treatment unless active infection occurs. Discuss with your provider for personalized risk, especially if unvaccinated or high-risk.[3][4]
[1] JAMA Dermatology study on biologics and COVID outcomes
[2] SECURE-SARS-CoV-2 trial in Rheumatology
[3] National Psoriasis Foundation COVID guidelines
[4] ACR COVID-19 vaccine guidance
[5] Case reports in Dermatology Therapy